Researchers have developed a new prognostic model for overall survival after first-line chemotherapy, which takes into account the advances that have been made in the treatment of metastatic castration-resistant prostate cancer (mCRPC) in recent years. Using data from a phase III trial of 1,050 men, the researchers used adaptive lasso (least absolute shrinkage and selection operator) to select eight prognostic factors (including disease site, lactate dehydrogenase and opioid analgesic use) that could be used to predict overall survival; they validated the model in an external set.